Late-Breaking Ph 2b RCT of TAK-279, oral TYK2 Inhib, in Active PsA. ACR20 in 53-54% (30 mg qd) vs 29.2% PBO at wk 12 (p = 0.002). Abst #L12 presented on Tuesday. #ACR23 

#ACR23 Abstr#0782 Triple therapy in #lupus nephritis. Propensity match data AURORA vs ALMS showed pts treated with voclosporin+MMF+low dose GC vs MMF+High dose GC achieved earlier reduction in UPCR & fewer AEs. Cdnt control for everything e.g. HCQ but assuring @RheumNow #ACRBest https://t.co/dmriAyQPr0

Clinical pearls in #CNS vasculitis: Dr. R.Hajj-Ali 🧠Clinical dx is difficult bec it presents w/ an array of clinical features 🧠CSF analysis essential in dx; can r/o infexns 🧠Nonvasc imaging highly sensitive 🧠biopsy is valuable esp when alt dx is considered #ACR23 @RheumNow https://t.co/QOAfSHn8ND

What is D2T PsA? A proposal of definition in ABST0777 Thoughts: A lot of features are extrapolated from the EULAR RA definition RA & PsA population are hardly comparable Lack of emphasis more problematic domains ie. dactylitis Further work is required @RheumNow #ACR23 https://t.co/A28e6XBME3

DRESS-PS study LTE. 12 month observational extension. 114 patients PsA/AxSpA. Essentially patients TNFi tapered or not in T2T fashion. TNFi dose remained lower in tapering group but it is consistently creeping back up. Abstr#0775 @RheumNow #ACR23 https://t.co/aYoOl6Ccin https://t.co/BtMR95lIfs

Fascinating how upadacitinib may well have an effect on pain in RA, beyond inflammation. Now seen similar for bari in RA & guselkumab in PsA. And, if real, for some people could be a massive get. Love to see dedicated studies SELECT-COMPARE post-hoc #ACR23 ABST0429 @RheumNow https://t.co/Tk278mGJYY

MEDIPSA: probiotic vs PBO RCT in PsA 12 weeks Using strains Bifidobacterium and Lactobacillus No effect on DA or PROMs in PsA No effect on gut parameters either Good safety profile Wrong strains or not an generally efficient intervention? ABST0778 @RheumNow #ACR23 https://t.co/RPgT7LoRgC

What do you think of CAR T Rx in severe #SLE? @RheumNow @ACRheum #ACR23

Ab#0596 #ACR23 @RheumNow R Furie on Decravacitinib in SLE 48wk double-blind trial. PBO v DEU 3mgBID, 6 mgBID,12 mg qd Higher response, faster time to SRI(4), BICLA and dual response v PBO. More likely to sustain response from w32-48. https://t.co/M34d3nQmwv

LEGACY Cohort - Rx monitoring AZA/Tacro in SLE pregnancy Ab#0586 #ACR23 @RheumNow 70 pregnancie. 33% prescribed AZA, 9% TAC AZA - 91% subtherapeutic or non-adherent More likely in non-Caucasian, on steroids, longer SLE duration, prior lupus nephritis TAC - 3/6 therapeutic levels

Do probiotics improve psoriatic arthritis? Unfortunately no difference in disease activity compared to placebo. Limited effects on gut dysbiosis Minor effects on T cell composition @RheumNow #ACR23 Abs#0778 https://t.co/JuBesyfnV2

Targeted OX40L (co-stimulatory APC protein w/ possible polymorphisms in SLE) study by Womba et al, found OX40L targeted CAR-Tregs had superior in vitro suppression of activated T cells & dendritic cells relative to Control-Tregs. #ACR23 Abs 0799 https://t.co/GgCGGIvhHF @rheumnow https://t.co/GZMEUCTooh

Should the cost of #CAR-T stop us from considering in severe refractory #lupus? So far update of German group show remission - drug free and great safety. But hold on..we need RCTs with an active control and longer f/u, but I am impressed! #ACR23 #ACRbest @ACRheum @RheumNow #784 https://t.co/mRMWLCbpCY

Klein et al. 205 RA-ILD. MUC5B not significantly associated survival, although wide CIs, aHR 0.75 (0.45, 1.24). Abstr#0772 #ACR23 @RheumNow https://t.co/ZfIIr2BbbR https://t.co/47DPYWNpL9

#ACR23 tidbits from Sunday @ACRheum @RheumNow 1 Less steroids better w other #Rx in #GCA, #PMR, #SLE #nephritis, #nonrenal #lupus BUT NOT in Severe GCA 2 Trend for combined immune modulators in #lupus GN or w a #CNI 3 #HCQ is better than sliced bread in #SLE aim for drug level